Molecular Pathology in Drug Discovery and Development

Herausgegeben von Platero, J. Suso

• Gebundenes Buch

Produktbeschreibung

The pharmaceutical industry is looking for new ways to better identify populations that will react positively to new drugs, and molecular pathology can fill that need. Molecular Pathology in Drug Discovery and Development provides an authoritative overview of molecular pathology and its applications and explains the significance of molecular pathology approaches to drug discovery and development. This book is an essential resource for practitioners in drug discovery and development, preclinical and clinical researchers, toxicologists and pharmacologists, molecular and cell biologists, and pathologists.

---

Covers powerful new tools for drug development

Molecular pathology offers tools and techniques that can greatly enhance the drug discovery and development process, helping to make the promises of personalized medicine a reality. Molecular Pathology in Drug Discovery and Development provides an unmatched guide to this cutting-edge discipline and its applications to pharmaceutical science.

With contributions from leading lights in drug discovery, drug development, and molecular pathology balanced by a consistent editorial approach, this reference offers both an overview of molecular pathology and a close look at the methods as they are applied to the process of drug discovery and development. Presented as steps in the drug development process, the coverage includes the use of molecular pathology to:
Identify and validate new drug candidates
Enhance transcriptional profiling to better find and validate biomarkers
Assess toxicology
Employ toxicogenomics to identify genes relevant to the safety of compounds
Identify correct doses for different drugs
Identify patients for treatment
Develop molecular therapies
Further the new techniques of Immunohistochemistry and Immunofluorescence

With many tests and treatments already working today, drug research and development using molecular pathology has shown itself an extremely fruitful area. Molecular Pathology in Drug Discovery and Development gives practitioners an up-to-date resource on this highly active discipline and its role in furthering pharmaceutical research.

Produktdetails

• Verlag: Wiley & Sons
• Artikelnr. des Verlages: 14514559000
• 1. Auflage
• Seitenzahl: 376
• Erscheinungstermin: 1. August 2009
• Englisch
• Abmessung: 243mm x 162mm x 27mm
• Gewicht: 671g
• ISBN-13: 9780470145593
• ISBN-10: 0470145595
• Artikelnr.: 26432908

Autorenporträt

J. Suso Platero is Director of Oncology Biomarkers at Centocor. Formerly, he was associate director of molecular pathology at Bristol-Myers Squibb. Dr. Platero has more than ten years of experience in the discovery, development, and validation of assays for clinical purposes.

Inhaltsangabe

Preface. Contributors. 1 MOLECULAR PATHOLOGY AND DRUG DEVELOPMENT (Franz
Fogt and J. Suso Platero). 1.1. General Pathology. 1.2. General Aspects.
1.3. Molecular Pathology, the Molecular Way. 1.4. Application of Molecular
Pathology. 1.5. Molecular Pathology in Drug Development. 1.6.
Pharmaceutical Drug Development. References. 2 MOLECULAR PATHOLOGY IN
ONCOLOGY TARGET AND DRUG DISCOVERY (Rolf-P. Ryseck, Ricardo Attar, Matthew
V. Lorenzi, and Brent A. Rupnow). 2.1. Introduction. 2.2. History of
Chemotherapy and Cancer Drug Discovery. 2.3. Target-Based Drug Discovery.
2.4. Utilization of Molecular Pathology in the Discovery of Novel Cancer
Targets. 2.5. Hit Identifi cation and In Vitro Lead Optimization. 2.6.
Implications for Molecular Pathology in Cancer Drug Development and Use.
2.7. Summary and Future Considerations. References. 3 MOLECULAR PATHOLOGY
AND TRANSCRIPTIONAL PROFILING IN EARLY DRUG DEVELOPMENT (Cornelia Liedtke,
Lajos Pusztai, and W. Fraser Symmans). 3.1. Introduction. 3.2. Biomarkers
in Clinical Setting and in Early Drug Development. 3.3. Advantages of
Biomarker Implementation. 3.4. Changing Paradigm in Clinical Drug and
Biomarker Development. 3.5. Promises of Transcriptional Profiling. 3.6.
Biomarker Development and Validation Using Microarray Analysis. 3.7.
Neoadjuvant Chemotherapy as an Intriguing Model for Biomarker Development.
3.8. Transcriptional Profi ling for Identifi cation of Individual Genes as
Biomarkers. 3.9. Transcriptional Profi ling for the Definition of Multigene
Predictors Using .Transcriptional Profiling. 3.10. Novel Tools for Pathway
Analysis. 3.11. Implementation of Biomarkers into the Clinical Setting.
3.12. Conclusion. References. 4 MOLECULAR PATHOLOGY IN NONCLINICAL SAFETY
ASSESSMENT (Richard A. Westhouse). 4.1. Introduction. 4.2. Drug
Development. 4.3. Drug Discovery. 4.4. Biopharmaceuticals. 4.5. Summary.
References. 5 TOXICOGENOMICS IN DRUG DEVELOPMENT (Wayne R. Buck and Eric A.
G. Blomme). 5.1. Introduction. 5.2. Brief Overview of Large-Scale Gene
Expression Technologies. 5.3. Analysis of Microarray Data. 5.4. Application
of Toxicogenomics in Drug Development. 5.5. Considerations for
Toxicogenomic Study Design. 5.6. Overview of Major Regulatory Developments
Related to Use of Toxicogenomics in Drug Discovery and Development. 5.7.
Summary. References. 6 MOLECULAR PATHOLOGY AS A WAY TO FIND THE RIGHT DOSE
FOR A DRUG (F. Rojo, A. Rovira, S. Serrano, and J. Albanell). 6.1.
Introduction. 6.2. Anti-EGFR-Targeted Therapies: The Pharmacodynamic
Experience. 6.3. Molecular Pathology with Small Molecules Gefitinib and
Erlotinib. 6.4. Molecular Pathology with Cetuximab and Other Monoclonal
Antibodies to EGFR. 6.5. Proteasome Inhibitors: Pharmacodynamics on Blood
Samples. 6.6. Pharmacodynamics with Rapamycin Analogs. 6.7. Second
Generation of Targeted Therapies: Multitarget Agents. 6.8. Conclusions and
Perspectives: Phase 0 Clinical Trials. References. 7 MOLECULAR PATHOLOGY IN
LIFE-CYCLE MANAGEMENT IN DRUG DEVELOPMENT (Martha Quezado, Carlos A.
Torres-Cabal, and David Berman). 7.1. Introduction. 7.2. Molecular
Pathology Techniques. 7.3. Practical Applications of Molecular Pathology
Biomarkers. 7.4. Conclusion. References. 8 MOLECULAR PATHOLOGY AND
MOLECULAR THERAPY (Hewei Li). 8.1. Introduction. 8.2. Molecular Therapy
Strategies. 8.3. Molecular Therapy Clinical Trials. References. 9 MOLECULAR
PATHOLOGY: IMMUNOHISTOCHEMISTRY ASSAYS IN DRUG DEVELOPMENT PERFORMED BY A
CONTRACT RESEARCH LABORATORY (Frank Lynch and Steve Bernstein). 9.1.
Immunohistochemistry Is the Technique of Microscopic Visualization of
Target Proteins in Tissue Sections Using Specific Antibodies. 9.2. Basics
of the IHC Assay. 9.3. Immunohistochemistry Assay Development. 9.4. Sending
a Study to a Contract Laboratory vs. Running In-house. 9.5. Choosing and
Working with an Outside Laboratory-- Keys for a Succe.ssful
Relationship--What to Do before a Slide Is Stained. 9.6. Running and
Managing Outsourced Clinical Studies 9.7. Applications of IHC in Drug
Discovery and Development Process. 9.8. Conclusion. References. 10
QUANTIFICATION OF MOLECULAR PATHOLOGY: COLORIMETRIC IMMUNOHISTOCHEMISTRY
(Raphael Marcelpoil). 10.1. Introduction. 10.2. Imaging Devices and
Systems. 10.3. Quantifi cation: Introduction to Colorimetric Image
Analysis. 10.4. Measuring Colorimetric Information. 10.5. Chromogen
Separation. 10.6. Measuring Information. 10.7. Conclusion. References. 11
AQUA(r) TECHNOLOGY AND MOLECULAR PATHOLOGY (Mark Gustavson, Marisa
Dolled-Filhart, Jason Christiansen, Robert Pinard, and David Rimm). 11.1.
Introduction. 11.2. AQUA Technology--How It Works. 11.3. Standardization.
11.4. Quantification. 11.5. Localization. 11.6. Multiparametric Analysis.
11.7. Application of AQUA Technology to Drug Discovery and Companion
Diagnostics. 11.8. Summary and Conclusions. References. Index.